GSK plc (the 'Company')
Transaction notification
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Sally Jackson |
||||
b) |
Position/status |
SVP, Global Communications & CEO Office |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GSK plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
The sale of 9,000 Ordinary Shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
e) |
Date of the transaction |
2024-03-11 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Sally Jackson |
||||
b) |
Position/status |
SVP, Global Communications & CEO Office |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GSK plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
The sale of 4,340 Ordinary Shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
e) |
Date of the transaction |
2024-03-11 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dylan Jackson |
||||
b) |
Position/status |
PCA of Sally Jackson (SVP, Global Communications & CEO Office) |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GSK plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
The sale of 13,616 Ordinary Shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
e) |
Date of the transaction |
2024-03-11 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
|||||
a) |
Name |
Dylan Jackson |
||||
b) |
Position/status |
PCA of Sally Jackson (SVP, Global Communications & CEO Office) |
||||
c) |
Initial notification/ amendment |
Initial notification |
||||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
a) |
Name |
GSK plc |
||||
b) |
LEI |
5493000HZTVUYLO1D793 |
||||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
|||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB0009252882
|
||||
b) |
Nature of the transaction |
The sale of 2,476 Ordinary Shares |
||||
c) |
Price(s) and volume(s) |
|
||||
d) |
Aggregated information Aggregated volume Price |
N/A (single transaction)
|
||||
e) |
Date of the transaction |
2024-03-12 |
||||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Deborah Waterhouse |
|||
b) |
Position/status |
CEO, ViiV Healthcare and President, GSK Global Health |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
The sale of 60,000 Ordinary Shares |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.8004 |
60,000 |
|
||
|
|
|
|
||
d) |
Aggregated information
|
N/A (single transaction) |
|||
Aggregated volume Price |
|
||||
e) |
Date of the transaction |
2024-03-12 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Emma Walmsley |
|||
b) |
Position/status |
Chief Executive Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
7 (partnership shares) |
|
||
|
£16.6610 |
7 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
14 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Julie Brown |
|||
b) |
Position/status |
Chief Financial Officer |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
8 (partnership shares) |
|
||
|
£16.6610 |
8 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
16 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
James Ford |
|||
b) |
Position/status |
SVP and Group General Counsel, Legal and Compliance |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
8 (partnership shares) |
|
||
|
£16.6610 |
8 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
16 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Sally Jackson |
|||
b) |
Position/status |
SVP, Global Communications and CEO Office |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
7 (partnership shares) |
|
||
|
£16.6610 |
7 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
14 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
David Redfern |
|||
b) |
Position/status |
President Corporate Development |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
8 (partnership shares) |
|
||
|
£16.6610 |
8 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
16 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Regis Simard |
|||
b) |
Position/status |
President, Global Supply Chain |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
8 (partnership shares) |
|
||
|
£16.6610 |
8 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
16 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Philip Thomson |
|||
b) |
Position/status |
President, Global Affairs |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
8 (partnership shares) |
|
||
|
£16.6610 |
8 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
16 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Deborah Waterhouse |
|||
b) |
Position/status |
CEO, ViiV Healthcare and President, Global Health, GSK |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
7 (partnership shares) |
|
||
|
£16.6610 |
7 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
14 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |
1. |
Details of PDMR/person closely associated with them ('PCA') |
||||
a) |
Name |
Victoria Whyte |
|||
b) |
Position/status |
Company Secretary |
|||
c) |
Initial notification/ amendment |
Initial notification |
|||
2. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
a) |
Name |
GSK plc |
|||
b) |
LEI |
5493000HZTVUYLO1D793 |
|||
3. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
||||
a) |
Description of the financial instrument |
Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
|
|||
b) |
Nature of the transaction |
Acquisition of Ordinary Shares under the Company's Share Reward Plan |
|||
c) |
Price(s) and volume(s) |
|
Price(s) |
Volume(s) |
|
|
£16.6610 |
7 (partnership shares) |
|
||
|
£16.6610 |
7 (matching shares) |
|
||
|
|
|
|
||
d) |
Aggregated information
|
|
|||
Aggregated volume Price |
14 Ordinary Shares £16.6610 |
||||
e) |
Date of the transaction |
2024-03-11 |
|||
f) |
Place of the transaction
|
London Stock Exchange (XLON) |